Composition and methods for the treatment of cancer

• US 8,022,042 B2
• Filed: 01/29/2010
• Issued: 09/20/2011
• Est. Priority Date: 02/16/2006
• Status: Active Grant

• Current Assignee: KoDiscovery, LLC
• Original Assignee: Young Hee Ko
• Inventors: Ko, Young Hee
• Primary Examiner(s): HENLEY III, RAYMOND J
• Application Number:
  US12/697,169
• Publication Number:
  US 20100197612A1
• Time in Patent Office: 599 Days
• Field of Search: 514/23, 514/53, 514/54, 514/396, 514/557, 514/675
• US Class Current: 514/23
• CPC Class Codes: A61K 31/202 having three or more double bonds, e.g. linolenic eicosanoids, e.g. leukotrienes A61K31/557
• CPC Class Codes: A61K 31/40 having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
• CPC Class Codes: A61K 31/44 Non condensed pyridines; Hydrogenated derivatives thereof
• CPC Class Codes: A61K 31/70 Carbohydrates; Sugars; Derivatives thereof sorbitol A61K31/047
• CPC Class Codes: A61K 31/7072 having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
• CPC Class Codes: A61K 31/7076 containing purines, e.g. adenosine, adenylic acid
• CPC Class Codes: A61P 1/00 Drugs for disorders of the alimentary tract or the digestive system
• CPC Class Codes: A61P 1/16 for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
• CPC Class Codes: A61P 1/18 for pancreatic disorders, e.g. pancreatic enzymes
• CPC Class Codes: A61P 11/00 Drugs for disorders of the respiratory system
• CPC Class Codes: A61P 31/04 Antibacterial agents
• CPC Class Codes: A61P 31/10 Antimycotics
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

The present invention discloses anti-cancer compositions, and associated methods, including an anti-cancer composition comprising: a cellular energy inhibitor having the structure according to formula I

• • wherein X is selected from the group consisting of: a nitro, an imidazole, a halide, sulfonate, a carboxylate, an alkoxide, and amine oxide; and R is selected from the group consisting of: OR′, N(R″)₂, C(O)R′″, C1-C6 alkyl, C6-C12 aryl, C1-C6 heteroalkyl, a C6-C12 heteroaryl, H, and an alkali metal; where R′ represents H, alkali metal, C1-C6 alkyl, C6-C12 aryl or C(O)R′″, R″ represents H, C1-C6 alkyl, or C6-C12 aryl, and R′″ represents H, C1-C20 alkyl or C6-C12 aryl. The anti-cancer composition can additionally comprise at least one sugar, which stabilizes the cellular energy inhibitor by substantially preventing the inhibitor from hydrolyzing. Also, the anti-cancer composition can comprise a glycolysis inhibitor. Further, the anti-cancer composition can comprise a biological buffer that is present in an amount sufficient to at least partially deacidify the cellular energy inhibitor and neutralize metabolic by-products of the cellular energy inhibitor.

Claims

1. An anti-cancer composition comprising:

a) a cellular energy inhibitor having the structure according to formula I

2. The anti-cancer composition of claim 1, wherein R of formula (I) is OH and X of formula (I) is selected from the group consisting of:

a halide, a sulfonate, a carboxylate, an alkoxide, and an amine oxide.

3. The anti-cancer composition of claim 1, wherein the cellular energy inhibitor is a 3-halopyruvate selected from the group consisting of:

3-fluoropyruvate, 3-chloropyruvate, 3-bromopyruvate, 3-iodopyruvate, and combinations thereof.

4. The anti-cancer composition of claim 1, wherein the composition comprises a second sugar and a third sugar independently selected from the group consisting of mannitol, erytritol, isomalt, lactitol, maltitol, sorbitol, xyolitol, dulcitol, ribitol, inositol, and combinations thereof.

5. The anti-cancer composition of claim 4, wherein the sugars are glycerol, inositol, and sorbitol and wherein the composition comprises glycerol in a range from about 0.1 wt % to about 3 wt %, inositol in a range from about 1 wt % to about 5 wt %, and sorbitol in a range from about 30 wt% to about 50 wt %.

6. The anti-cancer composition of claim 1, wherein the glycolysis inhibitor is 2-deoxglucose.

7. The anti-cancer composition of claim 1, wherein the composition comprises the glycolysis inhibitor in a concentration from about 1 mM to about 5 mM.

8. The anti-cancer composition of claim 1, wherein the biological buffer is selected from the group consisting of a citrate buffer, a phosphate buffer, and an acetate buffer.

9. The anti-cancer composition of claim 1, wherein the biological buffer is a citrate buffer.

10. The anti-cancer composition of claim 1, wherein the by-product is a hydrogen halide and the biological buffer is sodium citrate.

11. The anti-cancer composition of claim 1, wherein the composition comprises the biological buffer in a concentration from about 1 mM to about 20 mM and maintains a physiological pH of 5.5 to 8.0.

12. The anti-cancer composition of claim 1, further comprising a halo monocarboxylate compound.

13. The anti-cancer composition of claim 12, wherein the halo monocarboxylate compound is 2-bromoacetate.

14. The anti-cancer composition of claim 12, wherein the composition comprises the halo monocarboxylate compound in a concentration from about 0.1 mM to about 0.5 mM.

15. The anti-cancer composition of claim 1, further comprising a mitochondrial inhibitor.

16. The anti-cancer composition of claim 15, wherein the mitochondrial inhibitor is selected from the group consisting of:

oligomycin, efrapeptin, aurovertin, and mixtures thereof.

17. The anti-cancer composition of claim 15, wherein the composition comprises the mitochondrial inhibitor in a concentration from about 0.01 mM to about 0.5 mM.

18. A method for the treatment of cancer, comprising administering to a subject the anti-cancer composition of claim 1 in a therapeutically effective amount.

22. The anti-cancer composition of claim 1, wherein the cancerous tumor is in a tissue selected from the group consisting of brain, colon, urogenital, lung, renal, prostate, pancreas, liver, esophagus, stomach, hematopoietic, breast, thymus, testis, ovarian, skin, bone marrow, and uterine.

19. A method of minimizing toxicity of a cellular energy inhibitor of formula (I) to a subject receiving the cellular energy inhibitor comprising, combining in the subject, the cellular energy inhibitor with a biological buffer that is present in an amount sufficient to at least partially deacidify the cellular energy inhibitor and neutralize metabolic by-products of the cellular energy inhibitor due to its chemical reaction and/or cellular metabolism:

25. The method of claim 19, wherein the cellular energy inhibitor is 3- bromopyruvate.

26. The method of claim 19, wherein the biological buffer is selected from the group consisting of a citrate buffer, a phosphate buffer, and an acetate buffer.

27. The method of claim 19, wherein the biological buffer is a citrate buffer.

28. The method of claim 19, wherein the biological buffer maintains a physiological pH of 4.0 to 8.5 in the subject.

29. The method of claim 19, wherein the biological buffer maintains a physiological pH of 5.5 to 8.0.

30. The method of claim 19, wherein the cellular energy inhibitor and biological buffer are present in a ratio ranging from 1:

1 to 1;

5 by mM.

20. A method of minimizing an adverse drug experience associated with administration of an anti-cancer composition to a subject, comprising administering the anti-cancer composition to the subject at a time when the subject'"'"'s blood insulin/glucagon ratio in the range of about 1 to about 10;

the anti-cancer composition comprising the inhibitor of formula (I);

23. The method of claim 20, wherein the cancerous tumor is in a tissue selected from the group consisting of brain, colon, urogenital, lung, renal, prostate, pancreas, liver, esophagus, stomach, hematopoietic, breast, thymus, testis, ovarian, skin, bone marrow, and uterine.

31. The method of claim 20, wherein the insulin/glucagon ratio is in the range of about 2 to about 5.

32. The method of claim 20, wherein the anti-cancer composition is administered to the subject after fasting for at least 4 hours.

33. The method of claim 20, wherein the administration is selected from the group consisting of:

inter-arterially, intravenously, inter-peritoneally, inhalation, intra-tumorally, orally, topically, and subcutaneously.

34. The method of claim 33, wherein the administration is inter-arterially.

35. The method of claim 20, wherein the anti-cancer composition is intra-arterially or intravenously administered for a duration from about 30 minutes to about 8 hours.

36. The method of claim 20, wherein the anti-cancer composition is intra-arterially or intravenously administered for a duration from about 3 hours to about 5 hours.

37. The method of claim 20, wherein the administration includes a regimen lasting from about 1 week to 24 weeks.

38. The method of claim 20, wherein the administration includes a therapeutically effective amount of the anti-cancer composition.

39. The method of claim 38, wherein the therapeutically effective amount includes a dosage of about 1 mM to about 10 mM of the anti-cancer composition in a volume of 25 ml to 1000 ml.

40. The method of claim 20, wherein the adverse drug experience is cachexia.

41. The method of claim 20, wherein the adverse drug experience is pain.

21. A method for assessing killing efficacy of an anti-cancer composition in a subject, comprising

a) measuring a lactic acid level in the subject prior to administration of the anti-cancer composition;

b) administering the anti-cancer composition to the subject;

c) measuring the lactic acid level in the subject after administration of the anti-cancer composition; and

d) determining the killing efficacy by measuring and/or correlating the difference between the lactic acid levels as a function of treatment time;

wherein the anti-cancer composition comprises

i) a cellular energy inhibitor having the structure according to formula I

24. The method of claim 21, wherein the cancerous tumor is in a tissue selected from the group consisting of brain, colon, urogenital, lung, renal, prostate, pancreas, liver, esophagus, stomach, hematopoietic, breast, thymus, testis, ovarian, skin, bone marrow, and uterine.

42. The method of claim 21, wherein the lactic acid levels are measured from a biological fluid from the subject.

43. The method of claim 42, wherein the biological fluid is selected from the group consisting of:

blood and blood fractions, tears, sweat, urine, ascitic fluid, saliva, and combinations thereof.

44. The method of claim 21, wherein measuring is by colormetry using lactic acid binding enzymes.

45. The method of claim 21, wherein the measuring is by dip-stick or strip methods.

46. The method of claim 21, wherein the measuring is by magnetic resonance imaging.